

Sectoral Asset Management

Sectoral is an investment advisor exclusively focused on the global healthcare sector. The company manages public and private equity healthcare strategies for investors around the world. Our clients include sovereign wealth funds, private banks and family offices. In addition, we have long-standing sub-advisory relationships with institutional investors.

Sectoral was founded in October 2000 by Jérôme Pfund, CFA and Michael Sjöström, CFA, based on the strong conviction that investing in innovative healthcare companies provides investors a superior risk-reward profile over the long term while driving lasting benefits for society through improved health and well-being.

Sectoral's investment philosophy is based on deep fundamental research in the healthcare sector. Investments are chosen using a focused selection process based on primary research of company fundamentals and close contact with company management to assess their science, strategy, financials and ESG characteristics.

As a signatory to the United Nations Principles for Responsible Investment (PRI), Sectoral Asset Management believes that responsible investing plays a role in achieving the best possible risk-adjusted returns. We aim to identify, monitor, and mitigate ESG risks and opportunities that are, or could become, material to the long-term performance of companies in our portfolios.

Core competencies

- Industry-leading, global sector specialist
- Primary research
- Alpha generation

Fund of the month

Strategic Certificate on the Ariane Sectoral Low EV Biotech Index

ISIN: CH1217102131 (Swiss Security Number: 121710213)

[Daily Factsheet](#)

- The strategy invests in 10-15 carefully selected biotech companies, specialized in developing innovative drugs and technologies.
- Selection criteria: low enterprise value quality biotech companies, with validated products or pipeline, clear catalyst path to value creation and cash runway to reach such catalyst(s).
- The strategy aims to outperform its benchmark, namely the XBI S&P Biotech.
- Potential performance triggers include a general return to "risk on" in the market as well as positive catalysts for the portfolio companies.

| | |
|---------------------------|--|
| Webpage | Certificate Ariane Sectoral Low EV Biotech Index |
| All investment strategies | Public Equity Offering / Private Equity Offering |
| Market Outlook | Public Equity Newsletter / Private Equity Newsletter |

Contact



Heidi Foppa, EMBA
Senior Regional Director
T +41 (0) 22 316 66 37
heidi@sectoral.com
www.sectoral.com

Note: This is an advertisement of the above-mentioned partner of bank zweiplus ltd. The partner is solely responsible for the content of this advertisement. Please note that this advertisement has not been reviewed by bank zweiplus ltd. Accordingly, we cannot accept any responsibility for its legality and/or content and expressly draw your attention to the fact that opinions, views and advice expressed in this advertisement do not originate from bank zweiplus ltd. This advertisement is for information purposes only and does not constitute investment advice or a recommendation to buy or sell financial products or to engage in any other transaction.